Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Items 601–700 of 999
Horvat, S., & Rupnik, M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01633 · Cited by 32
Najarian, A., Sharif, S., & Griffiths, M. W. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.12.004 · Cited by 30
Trindade, C. N. D. R., Domingues, R. M. C. P., & Ferreira, E. D. O. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.03.002 · Cited by 29
Shelby, R. D., Tengberg, N., Conces, M. R., Olson, J. K., Navarro, J. B., Bailey, M. T., Goodman, S. D., & Besner, G. E. (2019) · Journal of Investigative Surgery · doi:10.1080/08941939.2019.1571129 · Cited by 26
Cernat, R. C., & Scott, K. P. (2012) · Anaerobe · doi:10.1016/j.anaerobe.2012.04.007 · Cited by 28
Luo, Y., Zhang, W., Cheng, J.-W., Xiao, M., Sun, G.-R., Guo, C.-J., Liu, M.-J., Cong, P. S., & Kudinha, T. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s152724 · Cited by 28
“The only one A + B + CDT + strain belonged to ST1 (Table 3).”
InfluentialStone, N. E., Nunnally, A. E., Jimenez, V. M., Jr., Cope, E. K., Sahl, J. W., Sheridan, K. L., Hornstra, H., Vinocur, J., Settles, E. W., Headley, K. C., et al. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.03.017 · Cited by 29
How the Anaerobic Enteropathogen Clostridioides difficile Tolerates Low O 2 Tensions
Kint, N., Feliciano, C. A., Martins, M. C., Morvan, C., Fernandes, S. F., Folgosa, F., Dupuy, B., Texeira, M., & Martin‐Verstraete, I. (2020) · mBio · doi:10.1128/mbio.01559-20 · Cited by 45
“the major cause of antibiotic-associated diarrhea and pseudomembranous colitis (2).”
BackgroundNorsigian, C. J., Danhof, H. A., Ardis, C. K., Oezguen, N., Midani, F. S., Palsson, B. Ø., Savidge, T., Britton, R. A., Spinler, J. K., & Monk, J. M. (2020) · npj Systems Biology and Applications · doi:10.1038/s41540-020-00151-9 · Cited by 27
Guillemin, I., Marrel, A., Lambert, J., Beriot‐Mathiot, A., Doucet, C., Kazoglou, O., Luxemburger, C., Reygrobellet, C., & Arnould, B. (2014) · Patient · doi:10.1007/s40271-013-0043-y · Cited by 28
Archbald‐Pannone, L. R., McMurry, T. L., Guerrant, R. L., & Warren, C. A. (2015) · American Journal of Infection Control · doi:10.1016/j.ajic.2015.03.017 · Cited by 28
Robinson, K. S., Mousnier, A., Hemrajani, C., Fairweather, N. F., Berger, C. N., & Frankel, G. M. (2010) · Microbiology · doi:10.1099/mic.0.037259-0 · Cited by 28
“Clostridium difficile is an anaerobic, spore-forming, Grampositive pathogen and a leading cause of nosocomial infections (Bartlett et al., 1978; George et al., 1978; Rupnik et al., 2009; Voth & Ballard, 2005).”
BackgroundGateau, C., Deboscker, S., Couturier, J., Vogel, T., Schmitt, E., Muller, J., Ménard, C., Turcan, B., Syed-Zaidi, R., Youssouf, A., et al. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102087 · Cited by 28
Clostridium difficile Infection
Knight, C. L., & Surawicz, C. M. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.02.003 · Cited by 34
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
Mullane, K. M., & Chaparro-Rojas (2013) · Infection and Drug Resistance · doi:10.2147/idr.s24434 · Cited by 30
Fecal Transplant in Refractory Clostridium difficile Colitis
Kleger, A., Schnell, J., Essig, A., Wagner, M., Bommer, M., Seufferlein, T. T. W., & Härter, G. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0108 · Cited by 33
Increased toxin expression in a Clostridium difficile mfd mutant
Willing, S. E., Richards, E. J., Sempere, L., Dale, A. G., Cutting, S. M., & Fairweather, N. F. (2015) · BMC Microbiology · doi:10.1186/s12866-015-0611-5 · Cited by 32
“Clostridium difficile is an anaerobic, spore-forming Grampositive pathogen that is now recognized as the leading cause of antibiotic-associated diarrhea in health care settings [1].”
BackgroundLynch, M. J., Walsh, T., Marszalowska, I., Webb, A. E., MacAogain, M., Rogers, T. R., Windle, H. J., Kelleher, D. P., O’Connell, M. J., & Loscher, C. E. (2017) · BMC Evolutionary Biology · doi:10.1186/s12862-017-0937-8 · Cited by 34
“Infection usually occurs in hospitalised patients receiving broad-spectrum antibiotics [2, 3].”
Suppressive effect ofLactobacillus fermentumLim2 onClostridioides difficile027 toxin production
Yong, C. C., Lim, J., Kim, B., Park, D., & Oh, S. (2019) · Letters in Applied Microbiology · doi:10.1111/lam.13124 · Cited by 30
“…causing a wide spectrum of gastrointestinal illness, ranging from mild to profuse diarrhoea with abdominal pain, or more severe conditions such as pseudomembranous colitis, colonic perforation and sometimes even death (Borriello 1998; Dobson et al. 2003; Rupnik et al. 2009; Antharam et al. 2013).”
BackgroundType I Toxin-Antitoxin Systems in Clostridia
Soutourina, O. A. (2019) · Toxins · doi:10.3390/toxins11050253 · Cited by 29
“difficile is a Gram-positive, strictly anaerobic spore-forming bacterium that became one of the major nosocomial enteropathogens in the industrial countries [10,11].”
BackgroundEnterotoxic Clostridia:Clostridioides difficileInfections
Mileto, S. J., Das, A., & Lyras, D. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0015-2018 · Cited by 28
Lim, S., Knight, D. R., Moono, P., Foster, N. F., & Riley, T. V. (2020) · Environmental Microbiology Reports · doi:10.1111/1758-2229.12889 · Cited by 27
Schmidt, C. J., Wenndorf, K., Ebbers, M., Volzke, J., Müller, M., Strübing, J., Kriebel, K., Kneitz, S., Kreikemeyer, B., & Müller‐Hilke, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571049 · Cited by 30
A Highly Specific DNA Aptamer for RNase H2 from Clostridium difficile
Li, J., Gu, J., Zhang, H., Liu, R., Zhang, W., Mohammed‐Elsabagh, M., Xia, J., Morrison, D., Zakaria, S., Chang, D., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c20277 · Cited by 28
Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
Whaley, K. J., & Zeitlin, L. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1930847 · Cited by 32
“Clostridium difficile infection (CDI) is the main cause of infectious diarrhea in patients following hospitalization and antibiotic treatment.(16) In developed countries, C.”
BackgroundInfluentialVerma, S., Dutta, S., Firnberg, E., Phillips, L. E., Vinayek, R., & Nair, P. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251590 · Cited by 32
“difficile in humans, which under certain clinical conditions can produce toxins A and B, which cause colitis through disruption of tight junctions in the intestinal epithelial barrier after internalization by colonic epithelial cells, and glycosylation of Rho GTPases in colonic epithelial cells [31, 32].”
BackgroundBouvet, P., Ferraris, L., Dauphin, B., Popoff, M. R., Butel, M. J., & Aires, J. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00477-14 · Cited by 31
“Clostridium is a genus of medical importance that includes pathogens responsible for several diseases in adults and children, such as Clostridium difficile antibiotic-associated colitis and Clostridium perfringens enteric diseases (1, 2).”
BackgroundHuman microbiome versus food-borne pathogens: friend or foe
Josephs‐Spaulding, J., Beeler, E., & Singh, O. V. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7523-7 · Cited by 32
“It is far easier to determine toxinotypes in an animal outbreak than in an outbreak among several humans (Rupnik et al. 2009; Lindstrom et al. 2011).”
Wyche, T. P., Alvarenga, R. F. R., Piotrowski, J. S., Duster, M. N., Warrack, S. R., Cornilescu, G., Wolfe, T. J. D., Hou, Y., Braun, D. R., Ellis, G. A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00388 · Cited by 30
Gu, H., Ying-yin, Y., Wang, M., Chen, S., Wang, H., Li, S., Ma, Y., & Wang, J. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00531 · Cited by 35
“difficile mainly attributed to the action of the two large enterotoxins, TcdA and TcdB (Voth and Ballard, 2005; Rupnik et al., 2009; Awad et al., 2014).”
BackgroundInfluentialLi, R., Xiao, D., Yang, J., Sun, S., Kaplan, S. E., Li, Z., Niu, Y., Qiang, C., Zhai, Y., Wang, X., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01990-17 · Cited by 28
“Clinical symptoms associated with C. difficile infection (CDI) range from mild diarrhea to life-threatening pseudomembranous colitis (PMC) (3).”
Halstead, F. D., Ravi, A., Thomson, N. M., Nuur, M., Hughes, K., Brailey, M., & Oppenheim, B. A. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.10.012 · Cited by 27
Pioneering gut health improvements in piglets with phytogenic feed additives
Yu, S. J., Morris, A., Kayal, A., Milošević, I., Van, T. T. H., Bajagai, Y. S., & Stanley, D. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12925-2 · Cited by 34
“Many species within these genera have been associated with conditions such as food poisoning, enteritis, and other digestive disorders (Allos 2001; Rupnik et al. 2009).”
BackgroundCOVID-19 and Clostridioides difficile Coinfection Analysis in the Intensive Care Unit
Stoian, M., Andone, A., Boeriu, A. M., Bândilă, S. R., Dobru, D. E., Laszlo, S. Ș., Corău, D., Arbănași, E. M., Russu, E., & Stoian, A. (2024) · Antibiotics · doi:10.3390/antibiotics13040367 · Cited by 26
“CDI is easily transmitted through spores and appears in medical healthcare and the community [21].”
BackgroundDistribution and characterization of Clostridium difficile isolated from dogs in Japan
Usui, M., Suzuki, K., Oka, K., Miyamoto, K., Takahashi, M., Inamatsu, T., Kamiya, S., & Tamura, Y. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.10.002 · Cited by 25
In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile
Mathur, T., Barman, T. K., Kumar, M., Singh, D., Kumar, R., Khera, M. K., Yamada, M., Inoue, S., Upadhyay, D. J., & Masuda, N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02157-17 · Cited by 25
“Clostridium difficile is the leading cause of nosocomial infection and a global public health threat (1, 2).”
BackgroundGut colonization with vancomycin-resistant Enterococcus and risk for subsequent enteric infection
Axelrad, J. E., Lebwohl, B., Cuaresma, E., Cadwell, K., Green, P. H. R., & Freedberg, D. E. (2018) · Gut Pathogens · doi:10.1186/s13099-018-0259-4 · Cited by 27
Differential View on the Bile Acid Stress Response of Clostridioides difficile
Sievers, S., Metzendorf, N. G., Dittmann, S., Troitzsch, D., Gast, V., Tröger, S. M., Wolff, C., Zühlke, D., Hirschfeld, C., Schlüter, R., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00258 · Cited by 30
Boudry, P., Piattelli, E., Drouineau, E., Johann, P., Boutserin, A., Lejars, M., Hajnsdorf, E., Monot, M., Dupuy, B., Martin‐Verstraete, I., et al. (2021) · RNA Biology · doi:10.1080/15476286.2021.1882180 · Cited by 30
“adults from CDI, since antibiotic treatments induce a colonic dysbiosis state that subsequently facilitates the development of this pathogen from acquired or pre-existing spores in healthy carriers [2,3].”
BackgroundAlabdali, Y. A. J., Oatley, P., Kirk, J. A., & Fagan, R. P. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102379 · Cited by 26
“As current treatments largely rely on antibiotic therapy, with further consequent damage to the microbiota, recurrent disease is common and is associated with worse patient prognosis [3].”
BackgroundVázquez‐Cuesta, S., Villar-Gómara, L., Lozano-García, N., Fernández, A. I., Olmedo, M., Alcalá, L., Marín, M., Muñóz, P., Bouza, E., & Reigadas, E. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1130701 · Cited by 30
“The clinical severity of CDI can be classified as follows: absence of symptoms; mild, moderate, and severe disease; pseudomembranous colitis; and toxic megacolon, sepsis, and death (Rupnik et al., 2009).”
BackgroundDong, Q., Lin, H., Allen, M.-M., Garneau, J. R., Sia, J. K., Smith, R. C., Haro, F., McMillen, T. A., Pope, R. L., Metcalfe, C. K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112861 · Cited by 29
Scaria, J., Suzuki, H., Ptak, C. P., Chen, J.-W., Zhu, Y., Guo, X.-K., & Chang, Y.-F. (2015) · BMC Genomics · doi:10.1186/s12864-015-1663-5 · Cited by 26
“CDI can cause a varying range of diseases from mild diarrhea to fulminant colitis and death [4–6].”
BackgroundClostridium difficile infection in patients with inflammatory bowel disease
Czepiel, J., Biesiada, G., Perucki, W. H., & Mach, T. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.43572 · Cited by 26
“In the most severe cases, CDAD will cause micro ulcerations covered with mucous from shed epithelial cells [12, 16, 17].”
BackgroundClaro, T., Daniels, S. M., & Humphreys, H. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01011-14 · Cited by 26
“Clostridium difficile is a spore-forming anaerobic nosocomial pathogen associated with mild to life-threatening diarrhea or colitis (1, 2).”
BackgroundClostridium difficile infection and inflammatory bowel disease
Cojocariu, C., Stanciu, C., Stoica, O. C., Sîngeap, A.-M., Sfarti, C. V., Gîrleanu, I., & Trifan, A. V. (2014) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2014.14054 · Cited by 26
“After binding to receptors on the enterocyte, the toxin penetrates the cell through receptor-mediated endocytosis followed by glycosylation of Rho and Ras proteins, leading to disruption of the epithelial cytoskeleton, and subsequently to inflammatory diarrhea (38).”
BackgroundPotential of lactoferrin to prevent antibiotic-inducedClostridium difficileinfection
Chilton, C. H., Crowther, G. S., Śpiewak, K., Brindell, M., Singh, G., Wilcox, M. H., & Monaghan, T. M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv452 · Cited by 28
Orenstein, W. A., Gellin, B. G., Beigi, R. H., Despres, S., Lynfield, R., Maldonado, Y., Mouton, C. P., Rawlins, W. S., Rothholz, M. C., Smith, N., et al. (2016) · Public Health Reports · doi:10.1177/003335491613100105 · Cited by 28
Chen, S., Gu, H., Sun, C., Wang, H., & Wang, J. (2016) · Infection · doi:10.1007/s15010-016-0940-9 · Cited by 26
“About 3000 deaths attributable to CDI are reported annually in the United Kingdom [21, 24].”
BackgroundLiu, M., Yin, Q., Brennan, J. D., & Li, Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.08.015 · Cited by 26
“In the United States, about 15,000-20,000 patients die annually from CDI [6].”
BackgroundClostridium difficile colonization and infection in patients with hepatic cirrhosis
Dong, Y., Chen, Y., Lv, T., Huang, Y., Yang, J., Li, Y., Huang, J., & Li, L. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000596 · Cited by 27
“Clostridium difficile infection (CDI, active C. difficile infection resulting in disease symptoms), listed as the leading three hospital-acquired infections in the United States [1, 2], is responsible for up to 20–30%of antibiotic-associated diarrhoea and almost all the pseudomembranous colitis (PMC) [3, 4].”
BackgroundStructural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic
Scaiola, A., Leibundgut, M., Boehringer, D., Caspers, P., Bur, D., Locher, H. H., Rueedi, G., & Ritz, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-42155-4 · Cited by 26
Microbiota–gut–brain axis: the mediator of exercise and brain health
Kang, P., & Wang, A. (2024) · Psychoradiology · doi:10.1093/psyrad/kkae007 · Cited by 34
Ainoda, Y., Hikone, M., Tago, S., Fujita, T., Hirai, Y., Takeuchi, K., & Totsuka, K. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s85007 · Cited by 25
Akha, A. A. S., McDermott, A. J., Theriot, C. M., Carlson, P. E., Frank, C. R., McDonald, R. A., Falkowski, N. R., Bergin, I. L., Young, V. B., & Huffnagle, G. B. (2014) · Immunology · doi:10.1111/imm.12414 · Cited by 30
“It is the most prevalent cause of nosocomial infectious diarrhoea in antibiotic-treated patients [2-5].”
BackgroundFecal transplantation for the treatment of recurrentClostridium difficileinfection
Karadsheh, Z., & Sule, S. S. (2013) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.114163 · Cited by 29
“[4,5] One main reason for this growing problem is the emergence of newer, more virulent, and antibiotic‐resistant strains including (NAP/BI/027) among others.[4,6]”
BackgroundPaitan, Y., Miller-Roll, T., & Adler, A. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.016 · Cited by 25
Identification of Clostridium difficile Immunoreactive Spore Proteins of the Epidemic Strain R20291
Pizarro‐Guajardo, M., Ravanal, M. C., Paez, M. D., Callegari, E. A., & Paredes‐Sabja, D. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700182 · Cited by 25
Isidro, J., Menezes, J., Serrano, M., Borges, V., Paixão, P., Mimoso, M., Martins, F., Toscano, C., dos Santos, A. H., Henriques, A. O., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02994 · Cited by 29
Wang, P., Wu, D., Su, Y., Li, X., & Xie, B. (2021) · Bioresource Technology · doi:10.1016/j.biortech.2021.126257 · Cited by 26
Vendrik, K. E. W., Baktash, A., Goeman, J. J., Harmanus, C., Notermans, D. W., de Greeff, S. C., & Kuijper, E. J. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100424 · Cited by 25
Tashiro, S., Mihara, T., Sasaki, M., Shimamura, C., Shimamura, R., Suzuki, S., Yoshikawa, M., Hasegawa, T., Enoki, Y., Taguchi, K., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.08.008 · Cited by 33
Changes of poultry faecal microbiota associated with Clostridium difficile colonisation
Škraban, J., Džeroski, S., Ženko, B., Tušar, L., & Rupnik, M. (2013) · Veterinary Microbiology · doi:10.1016/j.vetmic.2013.04.014 · Cited by 25
“difficile has been linked to a disruption or specific changes in the normal intestinal microbiota (Buffie et al., 2012; Peterfreund et al., 2012; Rea et al., 2012; Rousseau et al., 2011; Rupnik et al., 2009).”
BackgroundMarsden, G. L., Davis, I. J., Wright, V. J., Sebaihia, M., Kuijper, E. J., & Minton, N. P. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-389 · Cited by 25
Inducing and Quantifying Clostridium difficile Spore Formation
Shen, A., Fimlaid, K. A., & Pishdadian, K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6361-4_10 · Cited by 25
Wu, X., Paskaleva, E. E., Mehta, K. K., Dordick, J. S., & Kane, R. S. (2016) · Scientific Reports · doi:10.1038/srep35616 · Cited by 27
Shaban, L., Ying, C., Fasciano, A. C., Lin, Y., Kaplan, D. L., Kumamoto, C. A., & Mecsas, J. C. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.02.006 · Cited by 25
“difficile can be very recalcitrant to clearance by antibiotics for several reasons (1, 3).”
BackgroundInfluentialAppaneal, H. J., Caffrey, A. R., Beganovic, M., Avramovic, S., & LaPlante, K. L. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz032 · Cited by 25
“lowing the end of CDI treatment, with most cases occurring within 1 to 3 weeks after treatment.(2,24,25,54,58) Additionally, most clinical trials have assessed out-”
BackgroundInducible Expression of spo0A as a Universal Tool for Studying Sporulation in Clostridium difficile
Dembek, M., Willing, S. E., Hong, H. A., Hosseini, S., Salgado, P. S., & Cutting, S. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01793 · Cited by 24
“…difficile, spo0A, spore, inducible expression, allele-coupled exchange, anhydrotetracycline INTRODUCTION Clostridium difficile is a Gram-positive, anaerobic, spore-forming pathogen and the leading cause of healthcare associated diarrhea worldwide (Rupnik et al., 2009; Smits et al., 2016).”
BackgroundWang, S., Zhu, D., & Sun, X. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00263-22 · Cited by 25
Chisholm, J. M., Putsathit, P., Riley, T. V., & Lim, S. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03582-22 · Cited by 37
“Previously rare community-associated CDI CA-CDI, defined as cases with symptom onset in the community and no history of hospitalization in the past 12 weeks or symptom onset within #48 h of hospital admission (11), has emerged to represent a sizable proportion of CDI cases (1).”
BackgroundInfluentialValdés, L., Gueimonde, M., & Ruas‐Madiedo, P. (2015) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2015.09.022 · Cited by 26
Secco, D., Balassiano, I. T., Boente, R. F., Miranda, K. R., Brazier, J., Hall, V., dos Santos-Filho, J., Lobo, L. A., Nouér, S. A., & Domingues, R. M. C. P. (2014) · Anaerobe · doi:10.1016/j.anaerobe.2014.05.013 · Cited by 24
“This strain is resistant to fluoroquinolones, has deletions in tcdC gene that seem to be related to an overproduction of A and B toxins, produces binary toxin, shows alterations in surface layer protein A (SlpA) associated with an increased adherence to human intestinal cells and has increased sporulation rates, which…”
InfluentialOutbreak of Clostridium difficilePCR ribotype 027 - the recent experience of a regional hospital
Oleastro, M., Coelho, M. C., Gião, M., Coutinho, S., Mota, S. M. D. S., dos Santos, A. H., Rodrigues, J., & Faria, D. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-209 · Cited by 24
“It is also an emerging pathogen in the community, and is spreading as well to animals used in food industry [6].”
BackgroundAdams, H. M., Li, X., Mascio, C. T. M., Chesnel, L., & Palmer, K. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00526-15 · Cited by 25
“Surotomycin is a rapidly bactericidal cyclic lipopeptide antibiotic that is in clinical trials for CDI treatment and that has demonstrated superiority over vancomycin in preventing CDI relapse.”
BackgroundInfluentialIsolation and Characterization of Clostridium difficile Toxin-Specific Single-Domain Antibodies
Hussack, G., Arbabi‐Ghahroudi, M., MacKenzie, C. R., & Tanha, J. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_14 · Cited by 24
IL-27/IL-27 Receptor Signaling Provides Protection in Clostridium difficile-Induced Colitis
Wang, L., Cao, J., Li, C., & Zhang, L. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix581 · Cited by 23
“difficile infection (CDI) occur annually, resulting in 15 000 to 20 000 deaths [3].”
BackgroundScaria, J., Mao, C., Chen, J., McDonough, S. P., Sobral, B., & Chang, Y.-F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078489 · Cited by 30
“Clostridium difficile is a toxin producing anaerobic bacillus and is the leading cause of hospital associated diarrhea in North America and Europe[1,2].”
Wu, X., Alam, M. Z., Feng, L., Tsutsumi, L. S., Sun, D., & Hurdle, J. G. (2013) · Journal of Applied Microbiology · doi:10.1111/jam.12344 · Cited by 24
“NAP1 strains are associated with increased disease severity and mortality and are prone to cause CDI that recur in patients following treatment (Gerding et al. 2008; Rupnik et al. 2009).”
InfluentialUpdate on Clostridium difficile infections
Monnier, A. L., Zahar, J., & Barbut, F. (2014) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2014.04.002 · Cited by 23
Hicke, B. J., Pasko, C., Groves, B., Ager, E. P. C., Corpuz, M., Frech, G. C., Munns, D., Smith, W., Warcup, A., Denys, G. A., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00621-12 · Cited by 23
“difficile causes a spectrum of disease from mild diarrhea to fulminant pseudomembranous colitis (4, 27).”
BackgroundCotL, a new morphogenetic spore coat protein of Clostridium difficile
Feliciano, C. A., Douché, T., Gianetto, Q. G., Matondo, M., Martin‐Verstraete, I., & Dupuy, B. (2018) · Environmental Microbiology · doi:10.1111/1462-2920.14505 · Cited by 26
Clostridium difficile in wild rodents and insectivores in the Netherlands
Krijger, I. M., Meerburg, B. G., Harmanus, C., & Burt, S. A. (2019) · Letters in Applied Microbiology · doi:10.1111/lam.13159 · Cited by 23
“The bacterium C. difficile not only causes disease in humans, it is also able to cause enteric disease in several animal species, such as horses, piglets, calves and other domestic animals (B averud 2002; Rupnik 2007; Rupnik et al. 2009; Kecerova et al. 2019).”
BackgroundImpact of Appendectomy on Gut Microbiota
Бабаханов, А. Т., ДЖУМАБЕКОВ, А. Т., Zhao, A., Kuandykov, Y., Tanabayeva, S. B., Fakhradiyev, I. R., Nazarenko, Y., & Saliev, T. M. (2021) · Surgical Infections · doi:10.1089/sur.2020.422 · Cited by 28
New ribotype Clostridioides difficile from ST11 group revealed higher pathogenic ability than RT078
Gu, W., Wang, W., Li, W., Li, N., Wang, Y., Zhang, W., Lü, C., Tong, P., Han, Y., Sun, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1900748 · Cited by 26
“Currently, Clostridioides difficile is the predominant antibiotic-associated enteropathogen, which causes diarrhoea or even pseudomembranous colitis, in hospitalized patients worldwide [1,2].”
BackgroundO’Reilly, C., O’Connor, P. M., O’Sullivan, Ó., Rea, M. C., Hill, C., & Ross, R. P. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15250 · Cited by 23
“Clostridioides difficile infection can cause acute diarrhoea and pseudomembranous colitis, which can lead to colonic perforation and, if untreated, ultimately death (Kelly & La Mont, 2008; Rupnik et al., 2009; Stanley et al., 2013).”
Backgroundvan Leeuwen, H. C., Klychnikov, O. I., Menks, M. A. C., Kuijper, E. J., Drijfhout, J. W., & Hensbergen, P. J. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.09.041 · Cited by 23
“Of note, Clostridium difficile, an emerging human pathogen responsible for antibiotic-associated diarrhea with potentially fatal pseudomembranous colitis, has only a single full length sortase gene (cd2718) [23,24].”
BackgroundTernan, N. G., Jain, S., Graham, R. L. J., & McMullan, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088960 · Cited by 25
Moorhead, S., Maclean, M., Coia, J. E., MacGregor, S. J., & Anderson, J. G. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.12.006 · Cited by 23
“This could have significant advantages due to the recognised handling concerns, such as cutaneous and respiratory irritation associated with long term use as well as material damage, such as corrosion and pitting on equipment and surfaces, associated with the use of high strength chlorinated disinfectants [7,48].”
BackgroundKumar, R., Maynard, C. L., Eipers, P. G., Goldsmith, K. T., Ptacek, T., Grubbs, J. A., Dixon, P. B., Howard, D., Crossman, D. K., Crowley, M. R., et al. (2016) · BMC Microbiology · doi:10.1186/s12866-015-0622-2 · Cited by 27
Acácio, S., Nhampossa, T., Quintó, L., Vubil, D. C., Sacoor, C. N., Kotloff, K. L., Farag, T. H., Dilruba, N., Macete, E., Levine, M. M., et al. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.05.012 · Cited by 24
“Other studies have reported a high prevalence of C. difficile infections and associated disease among HIV-infected individuals (Haines et al., 2013), or an increased incidence of C. difficile in the general population (Rupnik et al., 2009).”
ResultGu, H., Qi, H., Chen, S., Shi, K., Wang, H., & Wang, J. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.05.052 · Cited by 19
Yee, K. L., Kleijn, H. J., Kerbusch, T., Matthews, R. P., Dorr, M. B., Garey, K. W., & Wrishko, R. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01971-18 · Cited by 24
“Clostridioides difficile (formerly Clostridium difficile), an anaerobic, spore-forming, Gram-positive bacillus, is the most common cause of infectious diarrhea in hospitalized patients given broad-spectrum antibiotics (1, 2).”
BackgroundBartlett, A., Gullickson, R. G., Singh, R., Ro, S., & Omaye, S. T. (2020) · Applied Sciences · doi:10.3390/app10186421 · Cited by 25
Flooding and Clostridium difficile Infection: A Case-Crossover Analysis
Lin, C. J., Wade, T. J., & Hilborn, E. D. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120606948 · Cited by 33
“hospitals and nursing homes per year [4,8].”
BackgroundUtility of Clostridium difficile Toxin B for Inducing Anti-Tumor Immunity
Huang, T., Li, S., Li, G., Tian, Y., Wang, H., Shi, L., Pérez‐Cordón, G., Mao, L., Wang, X., Wang, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110826 · Cited by 23
“Clostridium difficile is a major health care concern causing serious and potentially fatal through two major toxins, TcdA and TcdB [35,36,37].”
BackgroundRisk Factors for Recurrent Clostridium difficile Infection in Pediatric Inpatients
Schwab, E. M., Wilkes, J., Korgenski, K. E., Hersh, A. L., Pavia, A. T., & Stevens, V. W. (2016) · Hospital Pediatrics · doi:10.1542/hpeds.2015-0170 · Cited by 25
“The initial episodes were classified into the following epidemiologic groups: health care–associated CDI, community-associated CDI, or community onset-associated with health care.(14)”
Schneider, D., Thürmer, A., Gollnow, K., Lugert, R., Gunka, K., Groß, U., & Daniel, R. (2017) · Scientific Data · doi:10.1038/sdata.2017.152 · Cited by 23
Sheth, P. M., Douchant, K., Uyanwune, Y., Larocque, M., Anantharajah, A., Borgundvaag, E., Dales, L., McCreight, L. J., McNaught, L., Moore, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219579 · Cited by 23
Two case reports of Clostridium difficile bacteremia, one with the epidemic NAP-1 strain
Hemminger, J. A., Balada-Llasat, J.-M., Raczkowski, M., Buckosh, M., & Pancholi, P. (2011) · Infection · doi:10.1007/s15010-011-0115-7 · Cited by 22
“It is a frequent causative pathogen of antibiotic-associated diarrhea, as well as pseudomembranous colitis [2].”
BackgroundInfluential
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.